Analyst Reiterates Buy Rating and Maintains Price Target for Affimed - Best Stocks
| IMMNOV Stock | SEK 0.85 0.20 30.77% |
About 55% of Immunovia Publ's investors are presently thinking to get in. The analysis of current outlook of investing in Immunovia publ AB suggests that some traders are interested regarding Immunovia Publ's prospects. The current market sentiment, together with Immunovia Publ's historical and current headlines, can help investors time the market. In addition, many technical investors use Immunovia publ AB stock news signals to limit their universe of possible portfolio assets.
Immunovia |
Analyst Reiterates Buy Rating and Maintains Price Target for Affimed Best Stocks
Read at news.google.com
 |
Immunovia Publ Fundamental Analysis
We analyze Immunovia Publ's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovia Publ using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovia Publ based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Immunovia Publ is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Immunovia publ AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunovia Publ stock to make a market-neutral strategy. Peer analysis of Immunovia Publ could also be used in its relative valuation, which is a method of valuing Immunovia Publ by comparing valuation metrics with similar companies.
Peers
Immunovia Publ Related Equities
| CAMX | Camurus AB | 3.07 | ||||
| HNSA | Hansa Biopharma | 0.12 | ||||
| CANTA | Cantargia | 1.64 | ||||
| ONCO | Oncopeptides | 2.37 |
Complementary Tools for Immunovia Stock analysis
When running Immunovia Publ's price analysis, check to measure Immunovia Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovia Publ is operating at the current time. Most of Immunovia Publ's value examination focuses on studying past and present price action to predict the probability of Immunovia Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovia Publ's price. Additionally, you may evaluate how the addition of Immunovia Publ to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |